Overview

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

Status:
COMPLETED
Trial end date:
2024-06-13
Target enrollment:
Participant gender:
Summary
The purpose of this study to assess the relative bioavailability of 5 mg Mavacamten opened capsule administered via nasogastric tube compared to intact oral 5 mg Mavacamten in healthy volunteers.
Phase:
PHASE1
Details
Lead Sponsor:
Bristol-Myers Squibb